Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Seminars in Hematology|February 9, 2024
CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?Hannah Kinoshita, Catherine M Bollard, Keri TonerCase Reports in Critical Care|July 6, 2018
Central Pontine Myelinolysis in Pediatric Diabetic KetoacidosisHannah Kinoshita, Leon Grant, Konstantine Xoinis, et al.Children (Basel, Switzerland)|November 18, 2017
Optimal Line and Tube Placement in Very Preterm Neonates: An Audit of PracticeDaragh Finn, Hannah Kinoshita, Vicki Livingstone, et al.Transplantation and Cellular Therapy|March 3, 2025
T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell TherapyHannah Kinoshita, Carla S Walti, Kathleen Webber, et al.Blood Advances|January 1, 2024
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group studyBirte Wistinghausen, Keri Toner, Donald A Barkauskas, et al.Journal of Clinical Immunology|May 13, 2021
Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody DeficiencyHannah Kinoshita, Jessica Durkee-Shock, Mariah Jensen-Wachspress, et al.Blood Advances|December 14, 2022
Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell diseaseHannah Kinoshita, Mamatha Mandava, Mariah Jensen-Wachspress, et al.Frontiers in Immunology|February 4, 2022
SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 InfectionSusan R Conway, Christopher A Lazarski, Naomi E Field, et al.Blood Advances|March 4, 2022
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMTHannah Kinoshita, Kenneth R Cooke, Melanie Grant, et al.Pageof 1